Skip Navigation

Department of Health and Human Services

Agency for Healthcare Research Quality

AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español |

E-mail Updates

Home
Slides

Slide Tray

0 slides

View Empty Download

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"diagnostic testing"

Slides: 1–12 of 14

Add to tray Remove from tray

Overview: Objectives

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: diagnostic tests | objectives | prevention | treatment | overview

Add to tray Remove from tray

Overview: Methods

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: analysis | data sources | literature | methods | overview

Add to tray Remove from tray

Overview: Results for Diagnostic Testing

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: overview | diagnostic testing | immunoassays | sensitivity | specificity

Add to tray Remove from tray

Comparative Effectiveness of Diagnostic Assays for C.difficile

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: C. difficile Infection (CDI) | cell cytotoxicity assay | immunoassays | toxigenic culture | toxin gene detection | diagnostic assays

Add to tray Remove from tray

Assays Commonly Used in CDI Diagnostics

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: C. difficile Infection (CDI) | C. difficile culture | cytotoxicity assay | immunoassays | toxin gene detection | diagnostic assays

Add to tray Remove from tray

Methods Evaluated for Detecting Toxigenic C.difficile

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: C. difficile Infection (CDI) | glutamate dehydrogenase | immunoassays | toxin gene detection | diagnostic assays

Add to tray Remove from tray

Gaps in Knowledge

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention

Keywords: gaps in knowledge | diagnostic assays | prevention strategies | probiotics | prebiotics | fecal transplant | definitions

Add to tray Remove from tray

Conclusions (2 of 2)

Presentation: Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations

Keywords: antinuclear antibody | clinical assessment | connective tissue disease | cyclic-citrullinated peptide | inflammatory arthritis | rheumatoid factor | serological tests | study limitations | methodology

This slide discusses study population and applicability. It presents a table divided into two columns with one header row and six data rows. Column one is titled “Conditions that limit applicability” and column two is titled “Features that should be extracted into evidence tables.” Each of the six data rows contains conditions described in column one and associated features to be extracted in column two. In the first row, the limiting conditions are: narrow eligibility criteria, high exclusion rate, low enrollment. The features that should be extracted are: eligibility criteria and proportion of screened individuals enrolled. In the second row, limiting conditions are: differences between patients in study and the community. The features that should be extracted are: demographics (range and mean): age, gender, race and ethnicity. In the third row, the limiting conditions are: narrow or unrepresentative severity or stage of illness. The features that should be extracted are: severity or stage of illness (referral or primary care population). In the fourth row, limiting conditions are: run-in periods with high exclusion rates. The features that should be extracted are: run-in period: attrition rate before randomization and reason (e.g., nonadherence, adverse drug events and no response). In the fifth row, limiting conditions are: event rates markedly different than in community. The features that should be extracted are: event rates in treatment and control groups. In the sixth row, limiting conditions are: disease prevalence in study population different than community. The features that should be extracted are: prevalence of disease (for diagnostic studies).

Add to tray Remove from tray

Population and Applicability

Presentation: Assessing Applicability

Keywords: applicability | population | eligibility criteria | exclusion criteria

Data Elements: Population, Intervention, and Comparator. Population-generic elements may include patient characteristics, such as age, gender distribution, and disease stage. More specific items may be needed, depending upon the topic. Intervention or exposure and comparator items depend upon the abstracted study. Study types include randomized trial, observational study, diagnostic test study, prognostic factor study, family-based or population-based genetic study, et cetera.

Add to tray Remove from tray

Data Elements: Population, Intervention, and Comparator

Presentation: Data Extraction

Keywords: population | data extraction | intervention | comparator | PICOTS

Add to tray Remove from tray

Diagnosis and Treatment of Obstructive Sleep Apnea in Adults

Presentation: Diagnosis and Treatment of Obstructive Sleep Apnea in Adults

Keywords: comparative effectiveness review | diagnosis | systematic review | treatment | background

Add to tray Remove from tray

Background: Using Noninvasive Technologies To Diagnose Coronary Artery Disease (1 of 2)

Presentation: Noninvasive Technologies for Diagnosing Coronary Artery Disease in Women

Keywords: background | coronary artery disease | CAD | women | diagnosis | noninvasive technologies | symptomatic | asymptomatic

Pages: [1] 2 Next